Gapping down
In reaction to disappointing earnings/guidance: RT -14.2%, SEAC -10.1%, GPS -7%, (March comps) PSMT -4.2%,RECN -4.2%, ANGO -2.3%, WDFC -1%
Other news: VKTX -24.9% (following yesterday's 36% gain), NBIO -8.5% (granted orphan designation by the FDA for pritumumab for the treatment of pancreatic cancer), PSLV -4.2% (announces the launch of a follow-on offering of transferable, redeemable units of the trust), CME -2.5% (hearing attributed to a block trade), MOMO -1.7% (Alibaba confirms 27.7% active stake)
Analyst comments: AKS -2.2% (downgraded to Sell from Neutral at UBS), X -1.3% (downgraded to Sell from Neutral at UBS), VIAB -0.7% (initiated with an Underperform at RBC Capital Mkts)
In reaction to disappointing earnings/guidance: RT -14.2%, SEAC -10.1%, GPS -7%, (March comps) PSMT -4.2%,RECN -4.2%, ANGO -2.3%, WDFC -1%
Other news: VKTX -24.9% (following yesterday's 36% gain), NBIO -8.5% (granted orphan designation by the FDA for pritumumab for the treatment of pancreatic cancer), PSLV -4.2% (announces the launch of a follow-on offering of transferable, redeemable units of the trust), CME -2.5% (hearing attributed to a block trade), MOMO -1.7% (Alibaba confirms 27.7% active stake)
Analyst comments: AKS -2.2% (downgraded to Sell from Neutral at UBS), X -1.3% (downgraded to Sell from Neutral at UBS), VIAB -0.7% (initiated with an Underperform at RBC Capital Mkts)